$IVVD News

Invivyd Completes Enrollment In DECLARATION Phase 3 Trial of VYD2311 To Prevent Symptomatic Covid-19; Top-line Data Expected In Approximately Late Q3 2026

BTIG Reiterates Buy on Invivyd, Maintains $10 Price Target

BTIG Reiterates Buy on Invivyd, Maintains $10 Price Target

Invivyd (IVVD): 10 Best NASDAQ Stocks Under $5 to Buy Right Now

Invivyd, Inc. 2026 Q1 - Results - Earnings Call Presentation

Invivyd Inc (IVVD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments

Invivyd Q1 Earnings Call Highlights

Invivyd, Inc. (IVVD) Q1 2026 Earnings Call Transcript

Invivyd (NASDAQ:IVVD) Q1 Miss Sends Shares Lower as PEMGARDA Revenue Falls Short and R&D Costs Surge

Invivyd Reports First Quarter 2026 Financial Results and Recent Business Highlights

Invivyd Reports Q1 2026 Results: Full Earnings Call Transcript

Invivyd Q1 EPS $(0.13) Misses $(0.07) Estimate, Sales $13.744M Miss $18.050M Estimate

Invivyd and Collaborators Author New Manuscript Evaluating Early Tolerability of COVID Monoclonal Antibody and Comparing Results to COVID Vaccination

Invivyd EVADE Trial Data Reveals Monoclonal Antibody VYD2311 Demonstrates Minimal Tolerability Issues Versus COVID mRNA Vaccination

Invivyd to Host First Quarter 2026 Financial Results and Corporate Update Call on May 14, 2026

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd (IVVD) Announces Favorable Phase 3 Analysis for VYD2311 COVID-19 Treatment

Invivyd Announces Chairman Marc Elia to Speak at POLITICO Health Care Summit

Invivyd: Why The Trial Upsizing Isn't The Green Light Bulls Think It Is

Invivyd Updates VYD2311 REVOLUTION Trials, Modestly Upsizes Study, Unveils Measles mAb VMS-063